Advanced in Ulcerative Colitis

Dr. Doo-sang Cho

Gastroenterology
6020 E Arbor Ave, #101, 
Mesa, AZ 
 (2119.4 mi)
Advanced in Ulcerative Colitis
6020 E Arbor Ave, #101, 
Mesa, AZ 
 (2119.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Doo-sang Cho is a Gastroenterologist in Mesa, Arizona. Dr. Cho and is rated as an Advanced provider by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Esophagitis, Familial Adenomatous Polyposis, Ulcerative Colitis, and Gastroesophageal Reflux Disease (GERD).

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 5 clinical trials in the study of Ulcerative Colitis.

Specialties
Gastroenterology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

6020 E Arbor Ave, #101, Mesa, AZ 85206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials
Similar Doctors
Elite in Ulcerative Colitis
Dr. Christina Y. Ha
Gastroenterology
Elite in Ulcerative Colitis
Dr. Christina Y. Ha
Gastroenterology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (22.4 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christina Ha is a Gastroenterologist in Phoenix, Arizona. Dr. Ha and is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. Her top areas of expertise are Crohn's Disease, Ulcerative Colitis, Viral Gastroenteritis, Ileostomy, and Colonoscopy. Dr. Ha is currently accepting new patients.

Distinguished in Ulcerative Colitis
Dr. Jonathan A. Leighton
Gastroenterology
Distinguished in Ulcerative Colitis
Dr. Jonathan A. Leighton
Gastroenterology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (22.4 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Leighton is a Gastroenterologist in Phoenix, Arizona. Dr. Leighton and is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy.

Distinguished in Ulcerative Colitis
Dr. Shabana F. Pasha
Gastroenterology
Distinguished in Ulcerative Colitis
Dr. Shabana F. Pasha
Gastroenterology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (22.4 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shabana Pasha is a Gastroenterologist in Phoenix, Arizona. Dr. Pasha and is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. Her top areas of expertise are Crohn's Disease, Ulcerative Colitis, Colitis, Endoscopy, and Colonoscopy. Dr. Pasha is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile